Illumina, Inc.
0.0 %
-6.17 %
Yet to be announced
Company Overview
Illumina, Inc. is a global leader in DNA sequencing and array-based technologies. The company develops, manufactures, and markets life science tools and integrated systems for analyzing genetic variation and biological function. Their products enable customers to read and understand genetic variations at various levels of resolution.
The company's core business involves providing tools and services for genetic analysis, including sequencing instruments, consumables, and analysis tools used in genetic research, clinical diagnostics, and applied markets.
Revenue Sources
Based on a review of Illumina's business model and revenue sources, the company's primary income comes from the sale of genetic sequencing instruments, consumables, and related services. These products and services are used in medical research, diagnostics, and scientific applications, which are halal activities that benefit humanity.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 29, 2024 | $1.08b | $375.0m | - | $36.0m | 0.00% | 9.60% |
| June 30, 2024 | $1.11b | $2.77b | - | $20.0m | 0.00% | 0.72% |
| March 31, 2024 | $1.08b | $1.21b | - | $18.0m | 0.00% | 1.49% |
| Dec. 31, 2023 | $1.12b | $1.3b | - | $19.0m | 0.00% | 1.46% |
Analyzing the last four quarters: Interest expense ranged from $18 million to $36 million per quarter, while total expenses ranged from $375 million to $2.769 billion. The interest expense to total expense ratios remained below the 5% threshold for all quarters.
Operational Ethics
Based on available information from SEC filings and company reports, while Illumina has operations in various global markets, there is no evidence of material ongoing collaborations with entities involved in human rights violations. The company maintains standard commercial relationships in various markets but no direct significant ties to controversial entities have been identified.
Login to join the discussion